Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Angelica sinensis injection is a Traditional Chinese Medicine (TCM) preparation widely utilized in China for the management of musculoskeletal pain and inflammatory conditions. The formulation typically consists of an aqueous extract derived from the roots of *Angelica sinensis* (Danggui) combined with Vitamin B12 (cyanocobalamin). It is believed to exert therapeutic effects through anti-inflammatory, analgesic, and blood-circulation-promoting properties. In clinical practice, it is frequently administered via intra-articular or acupoint injection to treat conditions such as knee osteoarthritis, neuralgia, and sciatica. The botanical components, including ligustilide and ferulic acid, are thought to modulate inflammatory pathways, while Vitamin B12 supports peripheral nerve health and provides additional analgesic synergy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound angelica sinensis injection.